|Galectin Therapeutics, Inc.|
4960 Peachtree Industrial Boulevard
United States - Map
Galectin Therapeutics Inc., a development stage company, engages in the development of therapies for cancer and fibrotic disease. Its lead product candidates include GR-MD-02, a complex polysaccharide polymer for the treatment of liver fibrosis and fatty liver disease for which the company intends to initiate a Phase I clinical trial in patients with non-alcoholic steatohepatitis; and GM-CT-01, a linear polysaccharide polymer comprising mannose and galactose that is in a Phase I/II clinical trial in Europe as a combination therapy with a tumor vaccine in patients with advanced melanoma. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
|Mr. James C. Czirr ,
|Dr. Peter G. Traber M.D.,
Chief Exec. Officer, Pres, Chief Medical Officer and Director
|Dr. Harold H. Shlevin Ph.D.,
Chief Operating Officer and Corp. Sec.
|Mr. Thomas A. McGauley ,
Chief Financial Officer and Principal Accounting Officer
|Dr. Theodore D. Zucconi Ph.D.,
Director of Bus. Devel.
|Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|